FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - Today (New B) mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release -	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - Today mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release - Today - (New B)
HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 day (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1d	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 day IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1 day - (New B)
HR positive + BRCA1 mutation	HER2 Negative Breast Cancer	HR positive + BRCA1 mutation	HER2 Negative Breast Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 day (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1d	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 day IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1 day - (New B)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 2 days (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 2d	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 2 days IDE161 Sensitive : B IDEAYA Biosciences Press Release - 2 days - (New B)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 2 days (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 2d	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 2 days IDE161 Sensitive : B IDEAYA Biosciences Press Release - 2 days - (New B)
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials Businesswire - 2 days (New B) MYTX-011 Sensitive : B Businesswire - 2d	MYTX-011 Sensitive: B - Late Trials Businesswire - 2 days MYTX-011 Sensitive : B Businesswire - 2 days - (New B)
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	ABM-1310 Sensitive: B - Late Trials BioSpace - 2 days (New B) ABM-1310 Sensitive : B BioSpace - 2d	ABM-1310 Sensitive: B - Late Trials BioSpace - 2 days ABM-1310 Sensitive : B BioSpace - 2 days - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days (New A1) abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2d	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2 days - (New A1)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days (New A1) abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2d	abiraterone/niraparib Sensitive: A1 - Approval Korea Biomedical Review - 2 days abiraterone / niraparib Sensitive : A1 Korea Biomedical Review - 2 days - (New A1)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 2 days (New C3) aglatimagene besadenovec Sensitive : C3 BioSpace - 2d	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 2 days aglatimagene besadenovec Sensitive : C3 BioSpace - 2 days - (New C3)
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 2 days (New C3) aglatimagene besadenovec Sensitive : C3 BioSpace - 2d	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 2 days aglatimagene besadenovec Sensitive : C3 BioSpace - 2 days - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days (New A1) pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3d	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3 days - (New A1)
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days (New A1) pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3d	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval Chugai Press Release - 3 days pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 Chugai Press Release - 3 days - (New A1)
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lutetium Lu 177 dotatate Sensitive: B - Late Trials Novartis Press Release - 3 days (New B) lutetium Lu 177 dotatate Sensitive : B Novartis Press Release - 3d	lutetium Lu 177 dotatate Sensitive: B - Late Trials Novartis Press Release - 3 days lutetium Lu 177 dotatate Sensitive : B Novartis Press Release - 3 days - (New B)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	c-MET inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 3 days (New C3) c-MET inhibitor Sensitive : C3 JTO Clin Res Rep - 3d	c-MET inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 3 days c-MET inhibitor Sensitive : C3 JTO Clin Res Rep - 3 days - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 3 days (New C3) PD1 inhibitor Sensitive : C3 JTO Clin Res Rep - 3d	PD1 inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 3 days PD1 inhibitor Sensitive : C3 JTO Clin Res Rep - 3 days - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria Thorac Cancer - 5 days (New C3) pyrotinib Sensitive : C2 Thorac Cancer - 5d	pyrotinib Sensitive: C2 – Inclusion Criteria Thorac Cancer - 5 days pyrotinib Sensitive : C2 Thorac Cancer - 5 days - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 6 days (New B) nivolumab Sensitive : A1 Bristol-Myers Squibb Press Release - 6d	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 6 days nivolumab Sensitive : A1 Bristol-Myers Squibb Press Release - 6 days - (New B)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval Merck (MSD) Press Release - 6 days (New B) pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1 Merck (MSD) Press Release - 6d	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval Merck (MSD) Press Release - 6 days pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1 Merck (MSD) Press Release - 6 days - (New B)
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 6 days (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 6d	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 6 days capecitabine + mitomycin Sensitive : A2 NCCN - 6 days - (New A2)
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	gemcitabine Sensitive: A2 - Guideline NCCN - 6 days (New A2) gemcitabine Sensitive : A2 NCCN - 6d	gemcitabine Sensitive: A2 - Guideline NCCN - 6 days gemcitabine Sensitive : A2 NCCN - 6 days - (New A2)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days (New C3) afatinib Sensitive : A1 Thorac Cancer - 6d	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days afatinib Sensitive : A1 Thorac Cancer - 6 days - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days (New C3) afatinib Sensitive : A1 Thorac Cancer - 6d	afatinib Sensitive: A1 - Approval Thorac Cancer - 6 days afatinib Sensitive : A1 Thorac Cancer - 6 days - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval Thorac Cancer - 6 days (New C3) erlotinib Sensitive : A1 Thorac Cancer - 6d	erlotinib Sensitive: A1 - Approval Thorac Cancer - 6 days erlotinib Sensitive : A1 Thorac Cancer - 6 days - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	serplulimab Sensitive: A1 - Approval Henlius Press Release - 6 days (New A1) serplulimab Sensitive : A1 Henlius Press Release - 6d	serplulimab Sensitive: A1 - Approval Henlius Press Release - 6 days serplulimab Sensitive : A1 Henlius Press Release - 6 days - (New A1)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials Authorea - 6 days (New C3) icotinib Sensitive : B Authorea - 6d	icotinib Sensitive: B - Late Trials Authorea - 6 days icotinib Sensitive : B Authorea - 6 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	DS-1062a Sensitive: B - Late Trials AstraZeneca Press Release - 6 days (New B) DS-1062a Sensitive : B AstraZeneca Press Release - 6d	DS-1062a Sensitive: B - Late Trials AstraZeneca Press Release - 6 days DS-1062a Sensitive : B AstraZeneca Press Release - 6 days - (New B)
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	HER2 inhibitor Sensitive: C3 – Early Trials Br J Cancer - 6 days (New C3) HER2 inhibitor Sensitive : C3 Br J Cancer - 6d	HER2 inhibitor Sensitive: C3 – Early Trials Br J Cancer - 6 days HER2 inhibitor Sensitive : C3 Br J Cancer - 6 days - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 1 week (New B) pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 1 week - (New B)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cemiplimab-rwlc Sensitive: A1 - Approval NCCN - 1 week (New A2) cemiplimab-rwlc Sensitive : A1 NCCN - 1wk	cemiplimab-rwlc Sensitive: A1 - Approval NCCN - 1 week cemiplimab-rwlc Sensitive : A1 NCCN - 1 week - (New A2)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: A2 - Guideline J Neurooncol - 1 week (New C3) EGFR inhibitor Sensitive : A2 J Neurooncol - 1wk	EGFR inhibitor Sensitive: A2 - Guideline J Neurooncol - 1 week EGFR inhibitor Sensitive : A2 J Neurooncol - 1 week - (New C3)
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	ribociclib Sensitive: A2 - Guideline NCCN - 1 week (New A2) ribociclib Sensitive : A2 NCCN - 1wk	ribociclib Sensitive: A2 - Guideline NCCN - 1 week ribociclib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week (New B) belzutifan Sensitive : A2 Merck (MSD) Press Release - 1wk	belzutifan Sensitive: A2 - Guideline Merck (MSD) Press Release - 1 week belzutifan Sensitive : A2 Merck (MSD) Press Release - 1 week - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Breast Cancer Res Treat - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : A2 Breast Cancer Res Treat - 1wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Breast Cancer Res Treat - 1 week CDK4 inhibitor + CDK6 inhibitor Sensitive : A2 Breast Cancer Res Treat - 1 week - (New C3)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + sotorasib Sensitive : A2 NCCN - 1wk	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + sotorasib Sensitive : A2 NCCN - 1wk	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + adagrasib Sensitive : A2 NCCN - 1wk	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + adagrasib Sensitive : A2 NCCN - 1wk	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + sotorasib Sensitive : A2 NCCN - 1wk	panitumumab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + sotorasib Sensitive : A2 NCCN - 1wk	cetuximab + sotorasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + sotorasib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) panitumumab + adagrasib Sensitive : A2 NCCN - 1wk	panitumumab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week panitumumab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 1wk	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week capecitabine + mitomycin Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week (New A2) gemcitabine Sensitive : A2 NCCN - 1wk	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week gemcitabine Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 1wk	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week capecitabine + mitomycin Sensitive : A2 NCCN - 1 week - (New A2)
FOLR1 overexpression	Ovarian Cancer	FOLR1 overexpression	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials ESGO 2023 - 1 week (New B) mirvetuximab soravtansine-gynx Sensitive : B ESGO 2023 - 1wk	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials ESGO 2023 - 1 week mirvetuximab soravtansine-gynx Sensitive : B ESGO 2023 - 1 week - (New B)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 week (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 1 week - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval The Oncologist - 1 week (New C3) trastuzumab Sensitive : A1 The Oncologist - 1wk	trastuzumab Sensitive: A1 - Approval The Oncologist - 1 week trastuzumab Sensitive : A1 The Oncologist - 1 week - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ESGO 2023 - 1 week (New C3) olaparib Sensitive : A1 ESGO 2023 - 1wk	olaparib Sensitive: A1 - Approval ESGO 2023 - 1 week olaparib Sensitive : A1 ESGO 2023 - 1 week - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ESGO 2023 - 1 week (New C3) olaparib Sensitive : A1 ESGO 2023 - 1wk	olaparib Sensitive: A1 - Approval ESGO 2023 - 1 week olaparib Sensitive : A1 ESGO 2023 - 1 week - (New C3)
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval NICE - 1 week (New A2) pembrolizumab Sensitive : A1 NICE - 1wk	pembrolizumab Sensitive: A1 - Approval NICE - 1 week pembrolizumab Sensitive : A1 NICE - 1 week - (New A2)
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval Menarini Press Release - 1 week (New A1) elacestrant Sensitive : A1 Menarini Press Release - 1wk	elacestrant Sensitive: A1 - Approval Menarini Press Release - 1 week elacestrant Sensitive : A1 Menarini Press Release - 1 week - (New A1)
NTRK2 fusion	Thyroid Gland Papillary Carcinoma	NTRK2 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK3 fusion	Thyroid Gland Papillary Carcinoma	NTRK3 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK1 fusion	Thyroid Gland Papillary Carcinoma	NTRK1 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	abemaciclib Sensitive: A2 - Guideline NCCN - 1 week (New A2) abemaciclib Sensitive : A2 NCCN - 1wk	abemaciclib Sensitive: A2 - Guideline NCCN - 1 week abemaciclib Sensitive : A2 NCCN - 1 week - (New A2)
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week (New A2) cetuximab + adagrasib Sensitive : A2 NCCN - 1wk	cetuximab + adagrasib Sensitive: A2 - Guideline NCCN - 1 week cetuximab + adagrasib Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 positive	Cervical Cancer	HER-2 positive	Cervical Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 1 week (New A2) fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 positive	Endometrial Cancer	HER-2 positive	Endometrial Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 1 week (New A2) fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 1wk	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 1 week fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials Breast - 1 week (New C3) pyrotinib Sensitive : B Breast - 1wk	pyrotinib Sensitive: B - Late Trials Breast - 1 week pyrotinib Sensitive : B Breast - 1 week - (New C3)
TP53 wild-type	Endometrial Cancer	TP53 wild-type	Endometrial Cancer	selinexor Sensitive: B - Late Trials ESGO 2023 - 1 week (New B) selinexor Sensitive : B ESGO 2023 - 1wk	selinexor Sensitive: B - Late Trials ESGO 2023 - 1 week selinexor Sensitive : B ESGO 2023 - 1 week - (New B)
PD-L1 expression	Ovarian Cancer	PD-L1 expression	Ovarian Cancer	pembrolizumab Sensitive: C1 - Off-label ESGO 2023 - 1 week (New C4) pembrolizumab Sensitive : C1 ESGO 2023 - 1wk	pembrolizumab Sensitive: C1 - Off-label ESGO 2023 - 1 week pembrolizumab Sensitive : C1 ESGO 2023 - 1 week - (New C4)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week (New C4) trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1wk	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1 week - (New C4)
BRAF V600	Glioma	BRAF V600	Glioma	trametinib + dabrafenib Sensitive: C1 - Off-label N Engl J Med - 1 week (New C3) trametinib + dabrafenib Sensitive : C1 N Engl J Med - 1wk	trametinib + dabrafenib Sensitive: C1 - Off-label N Engl J Med - 1 week trametinib + dabrafenib Sensitive : C1 N Engl J Med - 1 week - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 1 week (New C3) bevacizumab Sensitive : C2 J Geriatr Oncol - 1wk	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 1 week bevacizumab Sensitive : C2 J Geriatr Oncol - 1 week - (New C3)
RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria Med Princ Pract - 1 week (New C3) cetuximab Sensitive : C2 Med Princ Pract - 1wk	cetuximab Sensitive: C2 – Inclusion Criteria Med Princ Pract - 1 week cetuximab Sensitive : C2 Med Princ Pract - 1 week - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 1 week (New C3) anlotinib + sintilimab Sensitive : C2 Cancer Med - 1wk	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 1 week anlotinib + sintilimab Sensitive : C2 Cancer Med - 1 week - (New C3)
CCR4 negative	Solid Tumor	CCR4 negative	Solid Tumor	mogamulizumab Sensitive: C2 – Inclusion Criteria PLoS One - 1 week (New C3) mogamulizumab Sensitive : C2 PLoS One - 1wk	mogamulizumab Sensitive: C2 – Inclusion Criteria PLoS One - 1 week mogamulizumab Sensitive : C2 PLoS One - 1 week - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Clin Cancer Res - 1 week (New C3) Immunotherapy Sensitive : C3 Clin Cancer Res - 1wk	Immunotherapy Sensitive: C3 – Early Trials Clin Cancer Res - 1 week Immunotherapy Sensitive : C3 Clin Cancer Res - 1 week - (New C3)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week (New C3) PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1wk	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1 week - (New C3)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week (New C3) PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1wk	PARP inhibitor Sensitive: C3 – Early Trials Eur Urol Oncol - 1 week PARP inhibitor Sensitive : C3 Eur Urol Oncol - 1 week - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + ramucirumab Sensitive: C3 – Early Trials J Clin Oncol - 1 week (New C3) trastuzumab + ramucirumab Sensitive : C3 J Clin Oncol - 1wk	trastuzumab + ramucirumab Sensitive: C3 – Early Trials J Clin Oncol - 1 week trastuzumab + ramucirumab Sensitive : C3 J Clin Oncol - 1 week - (New C3)
DLL3 overexpression	Small Cell Lung Cancer	DLL3 overexpression	Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials Br J Cancer - 1 week (New C3) PD-L1 inhibitor Resistant : C3 Br J Cancer - 1wk	PD-L1 inhibitor Resistant: C3 – Early Trials Br J Cancer - 1 week PD-L1 inhibitor Resistant : C3 Br J Cancer - 1 week - (New C3)
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 1 week - (New C3)
ER positive	Ovarian Cancer	ER positive	Ovarian Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 1 week - (New C3)
HER-2 expression	Endometrial Cancer	HER-2 expression	Endometrial Cancer	BNT323 Sensitive: C3 – Early Trials ESGO 2023 - 1 week (New C3) BNT323 Sensitive : C3 ESGO 2023 - 1wk	BNT323 Sensitive: C3 – Early Trials ESGO 2023 - 1 week BNT323 Sensitive : C3 ESGO 2023 - 1 week - (New C3)
CCR4 negative	Esophageal Cancer	CCR4 negative	Esophageal Cancer	mogamulizumab Sensitive: C3 – Early Trials PLoS One - 1 week (New C3) mogamulizumab Sensitive : C3 PLoS One - 1wk	mogamulizumab Sensitive: C3 – Early Trials PLoS One - 1 week mogamulizumab Sensitive : C3 PLoS One - 1 week - (New C3)
CCR4 negative	Lung Cancer	CCR4 negative	Lung Cancer	mogamulizumab Sensitive: C3 – Early Trials PLoS One - 1 week (New C3) mogamulizumab Sensitive : C3 PLoS One - 1wk	mogamulizumab Sensitive: C3 – Early Trials PLoS One - 1 week mogamulizumab Sensitive : C3 PLoS One - 1 week - (New C3)
GBP5 overexpression	Small Cell Lung Cancer	GBP5 overexpression	Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials J Inflamm Res - 1 week (New C3) Immunotherapy Sensitive : C3 J Inflamm Res - 1wk	Immunotherapy Sensitive: C3 – Early Trials J Inflamm Res - 1 week Immunotherapy Sensitive : C3 J Inflamm Res - 1 week - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) AZD3759 Sensitive : C3 EClinicalMedicine - 1wk	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week AZD3759 Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) AZD3759 Sensitive : C3 EClinicalMedicine - 1wk	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week AZD3759 Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
HR positive + TNFRSF11A overexpression	HER2 Negative Breast Cancer	HR positive + TNFRSF11A overexpression	HER2 Negative Breast Cancer	denosumab Sensitive: C3 – Early Trials Clin Cancer Res - 1 week (New C3) denosumab Sensitive : C3 Clin Cancer Res - 1wk	denosumab Sensitive: C3 – Early Trials Clin Cancer Res - 1 week denosumab Sensitive : C3 Clin Cancer Res - 1 week - (New C3)
SLC22A3 expression	Hepatocellular Cancer	SLC22A3 expression	Hepatocellular Cancer	sorafenib Sensitive: C3 – Early Trials Biochem Pharmacol - 1 week (New C3) sorafenib Sensitive : C3 Biochem Pharmacol - 1wk	sorafenib Sensitive: C3 – Early Trials Biochem Pharmacol - 1 week sorafenib Sensitive : C3 Biochem Pharmacol - 1 week - (New C3)
EGFR wild-type + Chr 11p11.11-q12.1	Non Small Cell Lung Cancer	EGFR wild-type + Chr 11p11.11-q12.1	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1 week - (New C3)
EGFR wild-type + Chr 9q21.31-q22.2	Non Small Cell Lung Cancer	EGFR wild-type + Chr 9q21.31-q22.2	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1 week - (New C3)
EGFR wild-type + Chr 7q31.1-q31.31	Non Small Cell Lung Cancer	EGFR wild-type + Chr 7q31.1-q31.31	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1 week - (New C3)
EGFR mutation + Chr 14q31.1-q31.3	Non Small Cell Lung Cancer	EGFR mutation + Chr 14q31.1-q31.3	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 1 week EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 1 week - (New C3)
EGFR mutation + Chr 1p13.3-p13.1	Non Small Cell Lung Cancer	EGFR mutation + Chr 1p13.3-p13.1	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials Pharmgenomics Pers Med - 1 week (New C3) EGFR inhibitor Resistant : C3 Pharmgenomics Pers Med - 1wk	EGFR inhibitor Resistant: C3 – Early Trials Pharmgenomics Pers Med - 1 week EGFR inhibitor Resistant : C3 Pharmgenomics Pers Med - 1 week - (New C3)
PIK3CA E545K	Cervical Cancer	PIK3CA E545K	Cervical Cancer	pembrolizumab Sensitive: C4 – Case Studies ESGO 2023 - 1 week (New C4) pembrolizumab Sensitive : C4 ESGO 2023 - 1wk	pembrolizumab Sensitive: C4 – Case Studies ESGO 2023 - 1 week pembrolizumab Sensitive : C4 ESGO 2023 - 1 week - (New C4)
CCDC6‐RET fusion + TERT promotor mutation	Thyroid Gland Anaplastic Carcinoma	CCDC6‐RET fusion + TERT promotor mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: C4 – Case Studies ATA 2023 - 1 week (New C4) selpercatinib Sensitive : C4 ATA 2023 - 1wk	selpercatinib Sensitive: C4 – Case Studies ATA 2023 - 1 week selpercatinib Sensitive : C4 ATA 2023 - 1 week - (New C4)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	gilteritinib Sensitive: D – Preclinical Cancer Sci - 1 week (New D) gilteritinib Sensitive : D Cancer Sci - 1wk	gilteritinib Sensitive: D – Preclinical Cancer Sci - 1 week gilteritinib Sensitive : D Cancer Sci - 1 week - (New D)
LOX overexpression	Ovarian Cancer	LOX overexpression	Ovarian Cancer	cisplatin Sensitive: D – Preclinical ESGO 2023 - 1 week (New D) cisplatin Sensitive : D ESGO 2023 - 1wk	cisplatin Sensitive: D – Preclinical ESGO 2023 - 1 week cisplatin Sensitive : D ESGO 2023 - 1 week - (New D)
LOX overexpression	Ovarian Cancer	LOX overexpression	Ovarian Cancer	paclitaxel Sensitive: D – Preclinical ESGO 2023 - 1 week (New D) paclitaxel Sensitive : D ESGO 2023 - 1wk	paclitaxel Sensitive: D – Preclinical ESGO 2023 - 1 week paclitaxel Sensitive : D ESGO 2023 - 1 week - (New D)
RET-KIF5B fusion	Lung Cancer	RET-KIF5B fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week (New D) TAS0953 / HM06 Sensitive : D Nat Cancer - 1wk	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week TAS0953 / HM06 Sensitive : D Nat Cancer - 1 week - (New D)
RET-TRIM33 fusion	Lung Cancer	RET-TRIM33 fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week (New D) TAS0953 / HM06 Sensitive : D Nat Cancer - 1wk	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week TAS0953 / HM06 Sensitive : D Nat Cancer - 1 week - (New D)
RET C634W	Thyroid Gland Medullary Carcinoma	RET C634W	Thyroid Gland Medullary Carcinoma	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week (New D) TAS0953 / HM06 Sensitive : D Nat Cancer - 1wk	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week TAS0953 / HM06 Sensitive : D Nat Cancer - 1 week - (New D)
RET-CCDC6 fusion	Lung Cancer	RET-CCDC6 fusion	Lung Cancer	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week (New D) TAS0953 / HM06 Sensitive : D Nat Cancer - 1wk	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week TAS0953 / HM06 Sensitive : D Nat Cancer - 1 week - (New D)
HER-2 T862A + HER-2 L755S	Breast Cancer	HER-2 T862A + HER-2 L755S	Breast Cancer	poziotinib Sensitive: D – Preclinical Cancer Res - 1 week (New D) poziotinib Sensitive : D Cancer Res - 1wk	poziotinib Sensitive: D – Preclinical Cancer Res - 1 week poziotinib Sensitive : D Cancer Res - 1 week - (New D)
HER-2 T862A + HER-2 L755S	Breast Cancer	HER-2 T862A + HER-2 L755S	Breast Cancer	mobocertinib Sensitive: D – Preclinical Cancer Res - 1 week (New D) mobocertinib Sensitive : D Cancer Res - 1wk	mobocertinib Sensitive: D – Preclinical Cancer Res - 1 week mobocertinib Sensitive : D Cancer Res - 1 week - (New D)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval Eur Urol - 2 weeks (New B) avelumab Sensitive : A1 Eur Urol - 2wk	avelumab Sensitive: A1 - Approval Eur Urol - 2 weeks avelumab Sensitive : A1 Eur Urol - 2 weeks - (New B)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	NALIRIFOX Sensitive: A2 - Guideline Lancet - 2 weeks (New B) NALIRIFOX Sensitive : A2 Lancet - 2wk	NALIRIFOX Sensitive: A2 - Guideline Lancet - 2 weeks NALIRIFOX Sensitive : A2 Lancet - 2 weeks - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials Expert Opin Pharmacother - 2 weeks (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : B Expert Opin Pharmacother - 2wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials Expert Opin Pharmacother - 2 weeks CDK4 inhibitor + CDK6 inhibitor Sensitive : B Expert Opin Pharmacother - 2 weeks - (New C3)
HLA-A2 positive	Non Small Cell Lung Cancer	HLA-A2 positive	Non Small Cell Lung Cancer	OSE 2101 Sensitive: B - Late Trials Ann Oncol - 2 weeks (New B) OSE 2101 Sensitive : B Ann Oncol - 2wk	OSE 2101 Sensitive: B - Late Trials Ann Oncol - 2 weeks OSE 2101 Sensitive : B Ann Oncol - 2 weeks - (New B)
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	CPI-0209 Sensitive: B - Late Trials Morphosys Press Release - 2 weeks (New B) CPI-0209 Sensitive : B Morphosys Press Release - 2wk	CPI-0209 Sensitive: B - Late Trials Morphosys Press Release - 2 weeks CPI-0209 Sensitive : B Morphosys Press Release - 2 weeks - (New B)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval NPJ Breast Cancer - 2 weeks (New C3) atezolizumab Sensitive : A1 NPJ Breast Cancer - 2wk	atezolizumab Sensitive: A1 - Approval NPJ Breast Cancer - 2 weeks atezolizumab Sensitive : A1 NPJ Breast Cancer - 2 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks (New C3) afatinib Sensitive : A1 Thorac Cancer - 2wk	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks afatinib Sensitive : A1 Thorac Cancer - 2 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval Cancer Res - 2 weeks (New C3) abemaciclib Sensitive : A1 Cancer Res - 2wk	abemaciclib Sensitive: A1 - Approval Cancer Res - 2 weeks abemaciclib Sensitive : A1 Cancer Res - 2 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: B - Late Trials Nat Med - 2 weeks (New C3) amivantamab-vmjw Sensitive : B Nat Med - 2wk	amivantamab-vmjw Sensitive: B - Late Trials Nat Med - 2 weeks amivantamab-vmjw Sensitive : B Nat Med - 2 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks (New C3) amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2wk	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks (New B) lazertinib Sensitive : B J Thorac Oncol - 2wk	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks lazertinib Sensitive : B J Thorac Oncol - 2 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks (New B) lazertinib Sensitive : B J Thorac Oncol - 2wk	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 2 weeks lazertinib Sensitive : B J Thorac Oncol - 2 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials Cancer Res Commun - 2 weeks (New D) ado-trastuzumab emtansine + tucatinib Sensitive : B Cancer Res Commun - 2wk	ado-trastuzumab emtansine + tucatinib Sensitive: B - Late Trials Cancer Res Commun - 2 weeks ado-trastuzumab emtansine + tucatinib Sensitive : B Cancer Res Commun - 2 weeks - (New D)
HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria J Transl Med - 2 weeks (New D) neratinib Sensitive : C2 J Transl Med - 2wk	neratinib Sensitive: C2 – Inclusion Criteria J Transl Med - 2 weeks neratinib Sensitive : C2 J Transl Med - 2 weeks - (New D)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks (New C3) U3-1402 Sensitive : C2 J Clin Oncol - 2wk	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks U3-1402 Sensitive : C2 J Clin Oncol - 2 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks (New C3) U3-1402 Sensitive : C2 J Clin Oncol - 2wk	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 weeks U3-1402 Sensitive : C2 J Clin Oncol - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 2 weeks (New C3) ramucirumab Sensitive : C2 ESMO Open - 2wk	ramucirumab Sensitive: C2 – Inclusion Criteria ESMO Open - 2 weeks ramucirumab Sensitive : C2 ESMO Open - 2 weeks - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 2 weeks (New C3) anlotinib Sensitive : C2 Int J Gen Med - 2wk	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 2 weeks anlotinib Sensitive : C2 Int J Gen Med - 2 weeks - (New C3)
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	CT041 Sensitive: C2 – Inclusion Criteria J Hematol Oncol - 2 weeks (New C4) CT041 Sensitive : C2 J Hematol Oncol - 2wk	CT041 Sensitive: C2 – Inclusion Criteria J Hematol Oncol - 2 weeks CT041 Sensitive : C2 J Hematol Oncol - 2 weeks - (New C4)
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
HER-2 M774delinsWLV	Non Small Cell Lung Cancer	HER-2 M774delinsWLV	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 2 weeks (New C3) EGFR inhibitor Sensitive : C3 BMC Cancer - 2wk	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 2 weeks EGFR inhibitor Sensitive : C3 BMC Cancer - 2 weeks - (New C3)
CHRNA6 overexpression	Lung Cancer	CHRNA6 overexpression	Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Curr Pharm Des - 2 weeks (New C3) Immunotherapy Sensitive : C3 Curr Pharm Des - 2wk	Immunotherapy Sensitive: C3 – Early Trials Curr Pharm Des - 2 weeks Immunotherapy Sensitive : C3 Curr Pharm Des - 2 weeks - (New C3)
miR-18a overexpression	Colorectal Cancer	miR-18a overexpression	Colorectal Cancer	FOLFOX Sensitive: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks (New C3) FOLFOX Sensitive : C3 Cancer Rep (Hoboken) - 2wk	FOLFOX Sensitive: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks FOLFOX Sensitive : C3 Cancer Rep (Hoboken) - 2 weeks - (New C3)
EGFR D770 delinsGY	Non Small Cell Lung Cancer	EGFR D770 delinsGY	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR exon 18 deletion	Non Small Cell Lung Cancer	EGFR exon 18 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR L747P	Non Small Cell Lung Cancer	EGFR L747P	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	methotrexate Sensitive: C4 – Case Studies BMC Womens Health - 2 weeks (New C4) methotrexate Sensitive : C4 BMC Womens Health - 2wk	methotrexate Sensitive: C4 – Case Studies BMC Womens Health - 2 weeks methotrexate Sensitive : C4 BMC Womens Health - 2 weeks - (New C4)
TMB-H	Thyroid Gland Medullary Carcinoma	TMB-H	Thyroid Gland Medullary Carcinoma	Immunotherapy Sensitive: C4 – Case Studies Thyroid - 2 weeks (New C4) Immunotherapy Sensitive : C4 Thyroid - 2wk	Immunotherapy Sensitive: C4 – Case Studies Thyroid - 2 weeks Immunotherapy Sensitive : C4 Thyroid - 2 weeks - (New C4)
SETD2 deletion	Clear Cell Renal Cell Carcinoma	SETD2 deletion	Clear Cell Renal Cell Carcinoma	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks (New D) talazoparib Sensitive : D Cancer Res - 2wk	talazoparib Sensitive: D – Preclinical Cancer Res - 2 weeks talazoparib Sensitive : D Cancer Res - 2 weeks - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks (New D) sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2wk	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2 weeks - (New D)
KRAS G12C	Pancreatic Ductal Adenocarcinoma	KRAS G12C	Pancreatic Ductal Adenocarcinoma	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks (New D) sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2wk	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2 weeks - (New D)
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval Ann Oncol - 3 weeks (New B) enfortumab vedotin-ejfv Sensitive : A1 Ann Oncol - 3wk	enfortumab vedotin-ejfv Sensitive: A1 - Approval Ann Oncol - 3 weeks enfortumab vedotin-ejfv Sensitive : A1 Ann Oncol - 3 weeks - (New B)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	tisotumab vedotin-tftv Sensitive: A1 - Approval Seagen Press Release - 3 weeks (New B) tisotumab vedotin-tftv Sensitive : A1 Seagen Press Release - 3wk	tisotumab vedotin-tftv Sensitive: A1 - Approval Seagen Press Release - 3 weeks tisotumab vedotin-tftv Sensitive : A1 Seagen Press Release - 3 weeks - (New B)
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline J Neurooncol - 3 weeks (New C3) temozolomide Sensitive : A2 J Neurooncol - 3wk	temozolomide Sensitive: A2 - Guideline J Neurooncol - 3 weeks temozolomide Sensitive : A2 J Neurooncol - 3 weeks - (New C3)
TMB-H	Melanoma	TMB-H	Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline Clin Cancer Res - 3 weeks (New B) nivolumab + ipilimumab Sensitive : A2 Clin Cancer Res - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline Clin Cancer Res - 3 weeks nivolumab + ipilimumab Sensitive : A2 Clin Cancer Res - 3 weeks - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials Breast Cancer Res Treat - 3 weeks (New C3) gimeracil / oteracil / tegafur Sensitive : B Breast Cancer Res Treat - 3wk	gimeracil/oteracil/tegafur Sensitive: B - Late Trials Breast Cancer Res Treat - 3 weeks gimeracil / oteracil / tegafur Sensitive : B Breast Cancer Res Treat - 3 weeks - (New C3)
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials Ann Oncol - 3 weeks (New C3) ribociclib Sensitive : B Ann Oncol - 3wk	ribociclib Sensitive: B - Late Trials Ann Oncol - 3 weeks ribociclib Sensitive : B Ann Oncol - 3 weeks - (New C3)
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials Ann Oncol - 3 weeks (New C3) ribociclib Sensitive : B Ann Oncol - 3wk	ribociclib Sensitive: B - Late Trials Ann Oncol - 3 weeks ribociclib Sensitive : B Ann Oncol - 3 weeks - (New C3)
PD-L1 overexpression	Melanoma	PD-L1 overexpression	Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials Clin Cancer Res - 3 weeks (New B) nivolumab + ipilimumab Sensitive : B Clin Cancer Res - 3wk	nivolumab + ipilimumab Sensitive: B - Late Trials Clin Cancer Res - 3 weeks nivolumab + ipilimumab Sensitive : B Clin Cancer Res - 3 weeks - (New B)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval Roche Press Release - 3 weeks (New B) alectinib Sensitive : A1 Roche Press Release - 3wk	alectinib Sensitive: A1 - Approval Roche Press Release - 3 weeks alectinib Sensitive : A1 Roche Press Release - 3 weeks - (New B)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval Nihon Yakurigaku Zasshi - 3 weeks (New C3) sotorasib Sensitive : A1 Nihon Yakurigaku Zasshi - 3wk	sotorasib Sensitive: A1 - Approval Nihon Yakurigaku Zasshi - 3 weeks sotorasib Sensitive : A1 Nihon Yakurigaku Zasshi - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval JAMA Oncol - 3 weeks (New C3) durvalumab Sensitive : A1 JAMA Oncol - 3wk	durvalumab Sensitive: A1 - Approval JAMA Oncol - 3 weeks durvalumab Sensitive : A1 JAMA Oncol - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval Breast - 3 weeks (New C3) ribociclib Sensitive : A1 Breast - 3wk	ribociclib Sensitive: A1 - Approval Breast - 3 weeks ribociclib Sensitive : A1 Breast - 3 weeks - (New C3)
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	zimberelimab Sensitive: A1 - Approval PRNewswire - 3 weeks (New A1) zimberelimab Sensitive : A1 PRNewswire - 3wk	zimberelimab Sensitive: A1 - Approval PRNewswire - 3 weeks zimberelimab Sensitive : A1 PRNewswire - 3 weeks - (New A1)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) niraparib Sensitive : A2 NCCN - 3wk	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks niraparib Sensitive : A2 NCCN - 3 weeks - (New A2)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) niraparib Sensitive : A2 NCCN - 3wk	niraparib Sensitive: A2 - Guideline NCCN - 3 weeks niraparib Sensitive : A2 NCCN - 3 weeks - (New A2)
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline J Neurooncol - 3 weeks (New C3) temozolomide Sensitive : A2 J Neurooncol - 3wk	temozolomide Sensitive: A2 - Guideline J Neurooncol - 3 weeks temozolomide Sensitive : A2 J Neurooncol - 3 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials Lancet Oncol - 3 weeks (New C3) palbociclib Sensitive : B Lancet Oncol - 3wk	palbociclib Sensitive: B - Late Trials Lancet Oncol - 3 weeks palbociclib Sensitive : B Lancet Oncol - 3 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials Nat Commun - 3 weeks (New B) bevacizumab Sensitive : B Nat Commun - 3wk	bevacizumab Sensitive: B - Late Trials Nat Commun - 3 weeks bevacizumab Sensitive : B Nat Commun - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks (New B) amivantamab-vmjw Sensitive : B J&J Press Release - 3wk	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks amivantamab-vmjw Sensitive : B J&J Press Release - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 3 weeks (New B) amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 3wk	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 3 weeks amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 3 weeks - (New B)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: B - Late Trials Nat Commun - 3 weeks (New B) cetuximab Sensitive : B Nat Commun - 3wk	cetuximab Sensitive: B - Late Trials Nat Commun - 3 weeks cetuximab Sensitive : B Nat Commun - 3 weeks - (New B)
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label Clin Cancer Res - 3 weeks (New D) osimertinib Sensitive : C1 Clin Cancer Res - 3wk	osimertinib Sensitive: C1 - Off-label Clin Cancer Res - 3 weeks osimertinib Sensitive : C1 Clin Cancer Res - 3 weeks - (New D)
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	anlotinib Sensitive: C2 – Inclusion Criteria Front Oncol - 3 weeks (New C3) anlotinib Sensitive : C2 Front Oncol - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria Front Oncol - 3 weeks anlotinib Sensitive : C2 Front Oncol - 3 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria Lancet Oncol - 3 weeks (New C3) GDC-9545 Sensitive : C2 Lancet Oncol - 3wk	GDC-9545 Sensitive: C2 – Inclusion Criteria Lancet Oncol - 3 weeks GDC-9545 Sensitive : C2 Lancet Oncol - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials Front Oncol - 3 weeks (New C3) anlotinib Sensitive : C3 Front Oncol - 3wk	anlotinib Sensitive: C3 – Early Trials Front Oncol - 3 weeks anlotinib Sensitive : C3 Front Oncol - 3 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 3 weeks (New C3) ALK inhibitor Sensitive : C3 BMC Pulm Med - 3wk	ALK inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 3 weeks ALK inhibitor Sensitive : C3 BMC Pulm Med - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + regorafenib Sensitive: C3 – Early Trials Lancet - 3 weeks (New C3) nivolumab + regorafenib Sensitive : C3 Lancet - 3wk	nivolumab + regorafenib Sensitive: C3 – Early Trials Lancet - 3 weeks nivolumab + regorafenib Sensitive : C3 Lancet - 3 weeks - (New C3)
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials Oncology - 3 weeks (New C3) durvalumab + tremelimumab Sensitive : C3 Oncology - 3wk	durvalumab + tremelimumab Sensitive: C3 – Early Trials Oncology - 3 weeks durvalumab + tremelimumab Sensitive : C3 Oncology - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) ABT-869 Sensitive : C3 BMC Cancer - 3wk	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks ABT-869 Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) midostaurin Sensitive : C3 BMC Cancer - 3wk	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks midostaurin Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vinblastine Sensitive : C3 BMC Cancer - 3wk	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vinblastine Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vorinostat Sensitive : C3 BMC Cancer - 3wk	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vorinostat Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
TNFRSF18-H	Renal Cell Carcinoma	TNFRSF18-H	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks (New C3) nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3wk	nivolumab Sensitive: C3 – Early Trials Eur Rev Med Pharmacol Sci - 3 weeks nivolumab Sensitive : C3 Eur Rev Med Pharmacol Sci - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 3wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sorafenib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks (New C3) sunitinib Sensitive : C3 Cancer Control - 3wk	sunitinib Sensitive: C3 – Early Trials Cancer Control - 3 weeks sunitinib Sensitive : C3 Cancer Control - 3 weeks - (New C3)
FRS2 amplification + MDM2 amplification	Breast Cancer	FRS2 amplification + MDM2 amplification	Breast Cancer	ribociclib Sensitive: C3 – Early Trials Ann Oncol - 3 weeks (New C3) ribociclib Sensitive : C3 Ann Oncol - 3wk	ribociclib Sensitive: C3 – Early Trials Ann Oncol - 3 weeks ribociclib Sensitive : C3 Ann Oncol - 3 weeks - (New C3)
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	lurbinectedin Sensitive: D – Preclinical Clin Cancer Res - 3 weeks (New D) lurbinectedin Sensitive : D Clin Cancer Res - 3wk	lurbinectedin Sensitive: D – Preclinical Clin Cancer Res - 3 weeks lurbinectedin Sensitive : D Clin Cancer Res - 3 weeks - (New D)
HER-2 overexpression	Uterine Cancer	HER-2 overexpression	Uterine Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical Mol Cancer Ther - 3 weeks (New D) fam-trastuzumab deruxtecan-nxki Sensitive : D Mol Cancer Ther - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical Mol Cancer Ther - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : D Mol Cancer Ther - 3 weeks - (New D)
miR-186 overexpression	Breast Cancer	miR-186 overexpression	Breast Cancer	paclitaxel Sensitive: D – Preclinical Cancer Drug Resist - 3 weeks (New D) paclitaxel Sensitive : D Cancer Drug Resist - 3wk	paclitaxel Sensitive: D – Preclinical Cancer Drug Resist - 3 weeks paclitaxel Sensitive : D Cancer Drug Resist - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	PLX4720 + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks (New D) PLX4720 + axitinib Sensitive : D Thyroid - 3wk	PLX4720 + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks PLX4720 + axitinib Sensitive : D Thyroid - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks (New D) dabrafenib + axitinib Sensitive : D Thyroid - 3wk	dabrafenib + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks dabrafenib + axitinib Sensitive : D Thyroid - 3 weeks - (New D)
MCAM expression	Solid Tumor	MCAM expression	Solid Tumor	AMT-253 Sensitive: D – Preclinical Cancer Res - 3 weeks (New D) AMT-253 Sensitive : D Cancer Res - 3wk	AMT-253 Sensitive: D – Preclinical Cancer Res - 3 weeks AMT-253 Sensitive : D Cancer Res - 3 weeks - (New D)
MCAM expression	Melanoma	MCAM expression	Melanoma	AMT-253 Sensitive: D – Preclinical Cancer Res - 3 weeks (New D) AMT-253 Sensitive : D Cancer Res - 3wk	AMT-253 Sensitive: D – Preclinical Cancer Res - 3 weeks AMT-253 Sensitive : D Cancer Res - 3 weeks - (New D)
ATM W2845	Melanoma	ATM W2845	Melanoma	talazoparib + KU-55933 Sensitive: D – Preclinical Cancer Res Commun - 3 weeks (New D) talazoparib + KU-55933 Sensitive : D Cancer Res Commun - 3wk	talazoparib + KU-55933 Sensitive: D – Preclinical Cancer Res Commun - 3 weeks talazoparib + KU-55933 Sensitive : D Cancer Res Commun - 3 weeks - (New D)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1

Solid Tumor

Associations(16201)

Associations
(16201)